03737 ZHONGZHIPHARM
- 1.180
- -0.040-3.28%
ZHONGZHIPHARM News
Zhongzhi Pharmaceutical Holdings' (HKG:3737) Promising Earnings May Rest On Soft Foundations
Despite posting some strong earnings, the market for Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) stock hasn't moved much. We did some digging, and we found some concerning factors in the de
Zhi Tian Lai Spends CN¥6.0m On Zhongzhi Pharmaceutical Holdings Stock
Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$6.0m worth of stock, at
中智藥業：二零二三年年報
Chairman of Zhongzhi Pharmaceutical Holdings Zhi Tian Lai Buys More Stock
Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$4.0m worth of stock, at
Zhongzhi Pharmaceutical (03737.HK) received 3.36 million shares from Chairman and Executive Director Lai Zhijian
Gelonghui, April 5 | According to the latest equity disclosure data of the Stock Exchange, on April 3, 2024, Zhongzhi Pharmaceutical (03737.HK) was granted an increase of 3.36 million shares by Chairman and Executive Director Lai Zhifen on the market at an average price of HK$1.18 per share, involving approximately HK$3.965 million. After the increase in holdings, Lai Zhifian's latest shareholding was 543,899,800 shares, and the shareholding ratio increased from 62.59% to 62.98%.
Zhongzhi Pharmaceutical's Attributable Jumps in 2023
Zhongzhi Pharmaceutical (HKG:3737) said its profit attributable to the owners climbed to 162.8 million yuan in 2023 from 106.4 million yuan in 2022, according to a Hong Kong bourse filing on Friday. E
ZHONGZHIPHARM To Go Ex-Dividend On May 24th, 2024 With 0.03 HKD Dividend Per Share
March 25th - $ZHONGZHIPHARM(03737.HK)$ is trading ex-dividend on May 24th, 2024. Shareholders of record on May 27th, 2024 will receive 0.03 HKD dividend per share on June 13th, 2024. The ex-divide
Zhongzhi Pharmaceutical Announces 2023 Results Profit attributable to shareholders of 163 million yuan, a year-on-year increase of 53%
Zhongzhi Pharmaceutical (03737) announced its 2023 results, with revenue of approximately RMB 2.05 billion (same unit), up 12.3% year on year; gross profit of RMB 1,218 billion, up 13.6% year on year; profit attributable to the company's equity holders of RMB 163 million, up 53% year on year; profit per share of $0.19, with a final dividend of HK3 cents per share.
Zhongzhi Pharmaceutical (03737) will pay a final dividend of HK$0.03 per share on June 13
Zhongzhi Pharmaceutical (03737) issued an announcement that it will be distributed on June 13, 2024 until December 3, 2023...
Zhongzhi Pharmaceutical (03737) Announces 2023 Results Profit attributable to equity holders of $163 million, up 53% year-on-year, with final interest of HK3 HK cents per share
Zhongzhi Pharmaceutical (03737) announced its 2023 results, with revenue of approximately RMB 2.05 billion (same unit), same...
ZHONGZHIPHARM: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
ZHONGZHIPHARM: NOTIFICATION OF BOARD MEETING
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
[Company Yingxi] Zhongzhi Pharmaceutical (03737) expects net profit to increase by more than 50% last year
Jinwu Financial News | Zhongzhi Pharmaceutical (03737) is pleased to report a net profit increase of more than 50% over the same period last year for the year ending December 31, 2023. The increase in net profit is mainly due to the continued rise in demand for proprietary Chinese medicine products, which has led to a sharp increase in revenue from the Group's proprietary Chinese medicine sector.
Announcement selection: CNOOC's production target this year exceeds 700 million barrels; Fuyao Glass plans to use 5.75 billion yuan to build high-quality float glass and other projects
Guangshen Railway Co., Ltd. made a profit. It is expected to achieve net profit of about 1.02 billion yuan to 1.12 billion yuan in 2023, turning a year-on-year loss into a profit; shareholders of Innovation Qizhi promised not to reduce their holdings after the sales restriction period expires, involving 265 million H shares.
Zhongzhi Pharmaceutical: Increased Demand for Chinese Patented Medicines Supported Results
Zhongzhi Pharmaceutical: Increased Demand for Chinese Patented Medicines Supported Results
Zhongzhi Pharmaceutical Sees 2023 Net Profit to Increase by More Than 50% on Year
Zhongzhi Pharmaceutical Sees 2023 Net Profit to Increase by More Than 50% on Year
Zhongzhi Pharmaceutical (03737.HK) Yingxi: Annual net profit is expected to increase by more than 50%
Gelonghui, January 25 | Zhongzhi Pharmaceutical (03737.HK) announced that the Group's net profit is expected to increase by more than 50% in the 2023 fiscal year compared to the Group's audited net profit in the same period of 2022. The Group's anticipated increase in net profit in fiscal year 2023 is mainly due to a sharp increase in revenue from the Group's proprietary Chinese medicine sector due to the continued rise in demand for proprietary Chinese medicine products.
ZHONGZHIPHARM: POSITIVE PROFIT ALERT
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Analysis
Price Target
No Data
